Nuvigil (armodafinil)

Override(s)                      Approval Duration
Prior Authorization
Quantity Limit                      1 year

Medications                  Quantity Limit
Nuvigil (armodafinil) 50mg                              2 tablets per day
Nuvigil (armodafinil) 150mg, 200mg, 250mg tablets            1 tablet per day

APPROVAL CRITERIA
I. Individual has been on Nuvigil (armodafinil) in the past 180 days (medication samples/ coupons/ discount cards are excluded from consideration as a trial); OR

Requests for Nuvigil (armodafinil) may be approved for the treatment of excessive daytime sleepiness associated with narcolepsy type 1 or type 2 based on the following criteria:

I. Individual is 18 years of age or older; AND

II. Individual has a diagnosis of Narcolepsy type 1 (narcolepsy with cataplexy) confirmed by the presence of daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months and at least one of the following:
   a. Clear cataplexy (defined as “more than one episode of generally brief [<2 min]) usually bilaterally symmetrical, sudden loss of muscle tone with retained consciousness”); AND
   b. Multiple Sleep Latency Test (MSLT) showing one of the following:
      1. Mean sleep latency of less than 8 minutes with evidence of two sleep-onset rapid eye movement periods (SOREMPs) (ICSD-3, 2014); OR
      2. At least one SOREMP on MSLT and a SOREMP (less than 15 minutes) on the preceding overnight polysomnography (PSG);

   OR
   c. Cerebrospinal fluid hypocretin-1 deficiency (less than [<] 110 pg/mL or less than one-third of the normative values with the same standardized assay);

   OR

III. Individual is 18 years of age or older; AND

IV. Individual has a diagnosis of Narcolepsy type 2 confirmed by the following:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
WEB-PEC-0610-17
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

<table>
<thead>
<tr>
<th>Market</th>
<th>FL &amp; FH K</th>
<th>FL MMA</th>
<th>FL LTC</th>
<th>GA</th>
<th>KS</th>
<th>KY</th>
<th>LA</th>
<th>MD</th>
<th>NJ</th>
<th>NV</th>
<th>NY</th>
<th>TN</th>
<th>TX</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td>NA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*FHK- Florida Healthy Kids
